Comment: Clinical Pharmaceutics and Calcium–Ceftriaxone

Rapp RP , Kuhn R . Clinical pharmaceutics and calcium ceftriaxone. Ann Pharmacother 2007;41:2072. Epub 6 Nov 2007. DOI 10.1345/aph.1K410

Shiffman ML , Keith FB , Moore EW . Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990;99:1772–8.

Purdum PP , Shiffman ML , Moore EW . In vivo studies of biliary ceftriaxone excretion and solubility in guinea pig hepatic bile. J Lab Clin Med 1992;120:604–13.

Commission Nationale de Pharmacovigilance [Minutes of the January 31, 2006, Meeting]. May 16, 2006. http://afssaps.sante.fr/htm/1/pharmaco/cr060101.pdf (accessed 2007 Nov 8).

[Letter to professionals: ceftriaxone and physical–chemical incompatibilities, particularly with solutions containing calcium salts. Modifications to the product] French. November 30, 2006. http://afssaps.sante.fr/htm/10/filltrpsc/Lp061202.pdf (accessed 2007 Nov 8).

Belliard CR , Sibille G . [Anaphylactoid shock or precipitation of calcium–ceftriaxone in a premature newborn. A case report] French. Arch Pediatr 2007;14:199–200.

Information for healthcare professionals. September 2007. www.fda.gov/cder/drug/InfoSheets/HCP/ceftriaxone.htm (accessed 2007 Nov 8).

Important clarification of prescribing information (Rocephin). August 2007. www.fda.gov/MedWatch/safety/2007/Rocephin_HCP_august2007.pdf (accessed 2007 Nov 9).